| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Agatha A van der Klaauw, Jeroen J Bax, Gabe B Bleeker, Eduard R Holman, V Delgado, Johannes W A Smit, Johannes A Romijn, Alberto M Pereir. Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. European journal of endocrinology. vol 159. issue 6. 2009-01-05. PMID:18787048. |
cardiac manifestations of gh deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. |
2009-01-05 |
2023-08-12 |
Not clear |
| C Scaroni, R Selice, S Benedini, E De Menis, M Arosio, C Ronchi, M Gasperi, L Manetti, G Arnaldi, B Polenta, M Boscaro, N Albiger, E Martino, F Manter. Adrenal morpho-functional alterations in patients with acromegaly. Journal of endocrinological investigation. vol 31. issue 7. 2008-12-22. PMID:18787376. |
acromegaly is associated with a greater morbidity and higher incidence of tumors, possibly due to the permissive role of elevated gh and igf-i levels. |
2008-12-22 |
2023-08-12 |
Not clear |
| L I Slingerland, G Voorhout, A Rijnberk, H S Kooistr. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus. Domestic animal endocrinology. vol 35. issue 4. 2008-12-17. PMID:18801640. |
in this prospective study 16 cats with diabetes mellitus were examined for concurrent acromegaly by measuring plasma growth hormone (gh) and insulin-like growth factor-i concentrations, and magnetic resonance imaging (mri) of the pituitary fossa. |
2008-12-17 |
2023-08-12 |
Not clear |
| Andrew G Renehan, Bernadette M Brenna. Acromegaly, growth hormone and cancer risk. Best practice & research. Clinical endocrinology & metabolism. vol 22. issue 4. 2008-12-16. PMID:18971124. |
acromegaly is an endocrine disorder characterized by sustained hypersecretion of growth hormone (gh) with concomitant elevation of insulin-like growth factor i (igf-i) associated with premature mortality from cardiopulmonary diseases and certain malignancies. |
2008-12-16 |
2023-08-12 |
Not clear |
| Aleksandra Jawiarczyk, Marcin Kałuzny, Marek Bolanowski, Grazyna Bednarek-Tupikowsk. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Neuro endocrinology letters. vol 29. issue 4. 2008-11-12. PMID:18766168. |
additional metabolic effects of adding gh receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. |
2008-11-12 |
2023-08-12 |
Not clear |
| Aleksandra Jawiarczyk, Marcin Kałuzny, Marek Bolanowski, Grazyna Bednarek-Tupikowsk. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Neuro endocrinology letters. vol 29. issue 4. 2008-11-12. PMID:18766168. |
aim of study was to assess the effects of pegvisomant and octreotide lar treatment on gh and igf-1 levels, and glucose tolerance in acromegaly, and to assess efficacy and tolerability of rapid (after 7 days) pegvisomant dose titration. |
2008-11-12 |
2023-08-12 |
Not clear |
| Michael Grant, Haydar Alturaihi, Philippe Jaquet, Brian Collier, Ujendra Kuma. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular endocrinology (Baltimore, Md.). vol 22. issue 10. 2008-11-03. PMID:18653781. |
somatostatin (sst) analogs have been successfully used in the medical treatment of acromegaly, caused by gh hypersecreting pituitary adenomas. |
2008-11-03 |
2023-08-12 |
human |
| Laurence Katznelso. An update on treatment strategies for acromegaly. Expert opinion on pharmacotherapy. vol 9. issue 13. 2008-10-23. PMID:18710352. |
acromegaly is an insidious disease due to growth hormone (gh) hypersecretion from a pituitary adenoma, and is associated with multiple comorbidities and risk of premature mortality. |
2008-10-23 |
2023-08-12 |
Not clear |
| Keiji Tanimoto, Naomi Hizuka, Izumi Fukuda, Kazue Takano, Toshiaki Hanafus. The influence of age on the GH-IGF1 axis in patients with acromegaly. European journal of endocrinology. vol 159. issue 4. 2008-10-17. PMID:18653547. |
the purpose of this study was to investigate the influence of age on gh and igf1 axis, and complications in patients with acromegaly. |
2008-10-17 |
2023-08-12 |
Not clear |
| Robert Krysiak, Bogusław Okopień, Bogdan Mare. [Advances in the treatment of acromegaly]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. vol 24. issue 139. 2008-10-16. PMID:18634256. |
acromegaly is a slow developing chronic debilitating disease caused by a growth hormone (gh)-producing pituitary adenoma. |
2008-10-16 |
2023-08-12 |
Not clear |
| Robert Krysiak, Bogusław Okopień, Bogdan Mare. [Advances in the treatment of acromegaly]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. vol 24. issue 139. 2008-10-16. PMID:18634256. |
the clinical consequences of acromegaly result both from excess gh secretion and from mass effect of the pituitary tumour. |
2008-10-16 |
2023-08-12 |
Not clear |
| Vivien S Bonert, Laurence Kennedy, Stephan Petersenn, Ariel Barkan, John Carmichael, Shlomo Melme. Lipodystrophy in patients with acromegaly receiving pegvisomant. The Journal of clinical endocrinology and metabolism. vol 93. issue 9. 2008-10-09. PMID:18611977. |
pegvisomant, a gh receptor antagonist, suppresses serum igf-i levels into the normal range in more than 95% of patients with acromegaly. |
2008-10-09 |
2023-08-12 |
Not clear |
| C Höybye, V Chandramouli, S Efendic, A-L Hulting, B R Landau, W C Schumann, A Wajngo. Contribution of gluconeogenesis and glycogenolysis to hepatic glucose production in acromegaly before and after pituitary microsurgery. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 40. issue 7. 2008-10-06. PMID:18393170. |
the diabetogenic effect of excess growth hormone (gh) such as that in acromegaly is well known. |
2008-10-06 |
2023-08-12 |
Not clear |
| Peter Kamenicky, Say Viengchareun, Anne Blanchard, Geri Meduri, Philippe Zizzari, Martine Imbert-Teboul, Alain Doucet, Philippe Chanson, Marc Lombè. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology. vol 149. issue 7. 2008-09-22. PMID:18388193. |
our findings provide the first evidence that gh, in concert with igf-i, stimulates enac-mediated sodium transport in the late distal nephron, accounting for the pathogenesis of sodium retention in acromegaly. |
2008-09-22 |
2023-08-12 |
rat |
| Laure Cazabat, Jean-Claude Souberbielle, Philippe Chanso. Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary. vol 11. issue 2. 2008-09-19. PMID:18418712. |
in the vast majority of cases, basal serum gh and igf-1 levels are markedly increased in patients with obvious clinical signs and symptoms of acromegaly. |
2008-09-19 |
2023-08-12 |
Not clear |
| Laure Cazabat, Jean-Claude Souberbielle, Philippe Chanso. Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary. vol 11. issue 2. 2008-09-19. PMID:18418712. |
thus, from a pragmatic point of view, achieving a normal age-adjusted igf-1 level and a gh nadir below 1 microg/l during ogtt will probably remain relevant for defining remission and good disease control in terms of morbidity and mortality in acromegaly. |
2008-09-19 |
2023-08-12 |
Not clear |
| Hidetoshi Ikeda, Shinobu Takayas. A growth hormone-secreting adenoma with incomplete nerve bundle formation. Neuropathology : official journal of the Japanese Society of Neuropathology. vol 28. issue 3. 2008-09-09. PMID:18194142. |
a 47-year-old man presenting with acromegaly was revealed to have high serum gh and igf-1 levels. |
2008-09-09 |
2023-08-12 |
Not clear |
| Lise-Lott Norrman, Gudmundur Johannsson, Katharina S Sunnerhagen, Johan Svensso. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. The Journal of clinical endocrinology and metabolism. vol 93. issue 7. 2008-08-21. PMID:18397981. |
baseline characteristics and the effects of two years of growth hormone (gh) replacement therapy in adults with gh deficiency previously treated for acromegaly. |
2008-08-21 |
2023-08-12 |
Not clear |
| Lise-Lott Norrman, Gudmundur Johannsson, Katharina S Sunnerhagen, Johan Svensso. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. The Journal of clinical endocrinology and metabolism. vol 93. issue 7. 2008-08-21. PMID:18397981. |
the effects of gh replacement in gh-deficient (ghd) adults previously treated for acromegaly are not well known. |
2008-08-21 |
2023-08-12 |
Not clear |
| Merih Baykan, Cihangir Erem, Omer Gedikli, Arif Hacihasanoğlu, Turan Erdoğan, Mustafa Koçak, Sahin Kaplan, Abdülkadir Kiriş, Sükrü Celi. Assessment of the Tei index by tissue Doppler imaging in patients with acromegaly: serum growth hormone level is associated with the Tei index. Echocardiography (Mount Kisco, N.Y.). vol 25. issue 4. 2008-08-19. PMID:18177382. |
the aim of this study was to assess the tei index by tissue doppler imaging (tdi) and also to evaluate the correlation with growth hormone (gh) and the tei index and left ventricular (lv) function assessed by tdi in patients with acromegaly. |
2008-08-19 |
2023-08-12 |
Not clear |